BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 8413432)

  • 1. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
    Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
    Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
    N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
    Heit JA; Berkowitz SD; Bona R; Cabanas V; Corson JD; Elliott CG; Lyons R
    Thromb Haemost; 1997 Jan; 77(1):32-8. PubMed ID: 9031445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
    Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
    N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin prophylaxis in elective hip surgery.
    Turpie AG
    Acta Chir Scand Suppl; 1990; 556():103-7. PubMed ID: 1963014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement.
    Francis CW; Pellegrini VD; Leibert KM; Totterman S; Azodo MV; Harris CM; Cox C; Marder VJ
    Thromb Haemost; 1996 May; 75(5):706-11. PubMed ID: 8725709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
    Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
    N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke.
    Sandset PM; Dahl T; Stiris M; Rostad B; Scheel B; Abildgaard U
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():25-33. PubMed ID: 1962901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
    N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.